Aadi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AADI
AADI has one approved drug.
There are seven US patents protecting AADI drugs.
There are one hundred and thirty-eight patent family members on AADI drugs in thirty-three countries and fourteen supplementary protection certificates in seven countries.
Summary for Aadi
| International Patents: | 138 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Aadi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aadi Sub | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | 10,973,806 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aadi Sub | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | 12,061,183 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aadi Sub | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | 8,911,786 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aadi Sub | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | 10,705,070 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aadi Sub | FYARRO | sirolimus | POWDER;INTRAVENOUS | 213312-001 | Nov 22, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aadi Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101943230 | ⤷ Start Trial |
| China | 116585310 | ⤷ Start Trial |
| Hungary | E057175 | ⤷ Start Trial |
| Serbia | 62743 | ⤷ Start Trial |
| Japan | 2016011309 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aadi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0763039 | SPC/GB08/025 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119 |
| 0763039 | 18/2008 | Austria | ⤷ Start Trial | PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119 |
| 0648494 | 01C0037 | France | ⤷ Start Trial | PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926 |
| 0763039 | PA2008009,C0763039 | Lithuania | ⤷ Start Trial | PRODUCT NAME: TEMSIROLIMUSUM; REGISTRATION NO/DATE: EU/1/07/424/001 20071119 |
| 0401747 | 25/2001 | Austria | ⤷ Start Trial | PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
